Inhibitory activity of diarylamidine derivatives on murine leukemia L1210 cell growth Jan BalzariniErik de ClercqOtto Dann Preclinical Pages: 103 - 115
Heterogeneous responses of an in vitro model of human stomach cancer to anticancer drugs S. C. BarrancoC. M. Townsend Jr.W. R. Boerwinkle Preclinical Pages: 117 - 127
In vitro cellular characteristics and survival responses of human astrocytoma clones to chloroethyl-nitrosoureas and dianhydrogalactitol Norma H. RubinCacilda CasartelliS. C. Barranco Preclinical Pages: 129 - 137
Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system John D. CowanDaniel D. Von HoffGary M. Clark Preclinical Pages: 139 - 144
Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1 Tsuyoshi OkanoTakao OhnumaHan Jui Preclinical Pages: 145 - 150
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents Robert T. DorrDavid S. Alberts Clinical Pages: 151 - 159
Phase I study of 4-demethoxydaunorubicin Valeria BonfanteLaura FerrariGianni Bonadonna Clinical Pages: 161 - 168
Phase I clinical trial of a new anthracycline: 4′-o-tetrahydropyranyl adriamycin Makoto OgawaHiroaki MiyamotoHiroshi Nakada Clinical Pages: 169 - 172
Phase I trial of aclacinomycin-A Chatchada KaranesJohn D. YoungLaurence H. Baker Clinical Pages: 173 - 179
Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group William A. Knight IIIDaniel D. Von HoffStephen E. Jones Clinical Pages: 181 - 184
Phase II study of Baker's antifol (triazinate, TZT, NSC 139, 105) in advanced carcinoma of the ovary James C. ArseneauBrian BundyJackson Beecham Clinical Pages: 185 - 188